ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

10:30AM-12:30PM: Abstract Number: 2015

Clinical features of IgG4-related disease – a single centre experience

(2015–2051) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-10:45AM: Abstract Number: 1766

Clinical Impact of Incomplete B-cell Depletion in ANCA-Associated Vasculitis Patients Receiving Maintenance Rituximab Therapy: a Retrospective Study

Abstracts: Vasculitis – ANCA-Associated (1764–1769)

10:30AM-12:30PM: Abstract Number: 2522

Clinical Outcomes and Prognostic Impact of Cardiac and Cerebrovascular Involvement in Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Study

(2504–2523) Vasculitis – ANCA-Associated Poster III

10:30AM-12:30PM: Abstract Number: 2022

Clinical Predictors of Macrophage Activation Syndrome and Treatment Outcomes in Adult-Onset Still’s Disease: A 24-Year Single-Center Experience

(2015–2051) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 1910

Clinical profile and healthcare resource utilization of patients diagnosed with giant cell arteritis or polymyalgia rheumatica in the US: a real-world cohort study using a large database of administrative health claims

(1877–1913) Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 1961

Clinical Utility and Patient Experience of Ultrasound-Guided Synovial Biopsy in Refractory Arthritis: A Case Series from a Secondary Care Center

(1936–1971) Imaging of Rheumatic Diseases Poster

10:30AM-12:30PM: Abstract Number: 2297

Clinically Relevant Anti-Vaccine and Virus Antibodies in Patients with Sjogren’s Disease Treated with Nipocalimab: Post-Hoc Analysis of the DAHLIAS Study

(2290–2304) Sjögren’s Disease – Basic & Clinical Science Poster III: Treatment and Trial Outcome Measures

10:30AM-12:30PM: Abstract Number: 2293

CLN-978, a CD19 x CD3-Directed T Cell Engager, Leads to Rapid and Deep B Cell Depletion In Vitro and In Vivo, Supporting Clinical Development Across Multiple Autoimmune Diseases

(2290–2304) Sjögren’s Disease – Basic & Clinical Science Poster III: Treatment and Trial Outcome Measures

10:30AM-12:30PM: Abstract Number: 2422

Cluster Analysis of Autoantibodies in Patients with Systemic Lupus Erythematosus

(2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2302

Clustering by ESSPRI and PROMIS domain measures defines distinct subtypes and facilitates longitudinal assessment of patients with Sjogren’s disease

(2290–2304) Sjögren’s Disease – Basic & Clinical Science Poster III: Treatment and Trial Outcome Measures

10:30AM-12:30PM: Abstract Number: 1991

Co-Use of Mycophenolate Mofetil with Pegloticase Yielded Similar Clinical Outcomes as the Co-Use of Methotrexate

(1990–2014) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 2359

Combination Of TNF Inhibitors And NSAIDs Versus TNF Inhibitors Alone On The Progression Of Structural Damage In The Spine And Hip: a Retrospective Study In 262 Patients With Radiographic Axial Spondyloarthritis

(2338–2376) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2272

Combination Therapy with TNF Inhibitors and JAK Inhibitors in Multi-Drug-Resistant Rheumatoid Arthritis: A Case Series from the RA UCLouvain Brussels Cohort

(2265–2289) Rheumatoid Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2294

Comparative Analysis of Patients Included in Trials Utilizing Biologic Drugs in the Treatment of Primary Sjögren’s Syndrome

(2290–2304) Sjögren’s Disease – Basic & Clinical Science Poster III: Treatment and Trial Outcome Measures

10:30AM-12:30PM: Abstract Number: 2109

Comparative Effects of IL-6 inhibition, Methotrexate, and Glucocorticoid Monotherapy on Bone Mineral Density, 3D-DXA femoral structure and Bone Turnover Markers in GCA and PMR

(2106–2123) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].